Cargando…

Montelukast Use Decreases Cardiovascular Events in Asthmatics

Cysteinyl leukotrienes are proinflammatory mediators with a clinically established role in asthma and a human genetic and preclinical role in cardiovascular pathology. Given that cardiovascular disease has a critical inflammatory component, the aim of this work was to conduct an observational study...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoxha, Malvina, Tedesco, Calogero C., Quaglin, Silvana, Malaj, Visar, Pustina, Linda, Capra, Valerie, Evans, Jilly F., Sala, Angelo, Rovati, G. Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838535/
https://www.ncbi.nlm.nih.gov/pubmed/33519477
http://dx.doi.org/10.3389/fphar.2020.611561
_version_ 1783643201461026816
author Hoxha, Malvina
Tedesco, Calogero C.
Quaglin, Silvana
Malaj, Visar
Pustina, Linda
Capra, Valerie
Evans, Jilly F.
Sala, Angelo
Rovati, G. Enrico
author_facet Hoxha, Malvina
Tedesco, Calogero C.
Quaglin, Silvana
Malaj, Visar
Pustina, Linda
Capra, Valerie
Evans, Jilly F.
Sala, Angelo
Rovati, G. Enrico
author_sort Hoxha, Malvina
collection PubMed
description Cysteinyl leukotrienes are proinflammatory mediators with a clinically established role in asthma and a human genetic and preclinical role in cardiovascular pathology. Given that cardiovascular disease has a critical inflammatory component, the aim of this work was to conduct an observational study to verify whether the use of a cysteinyl leukotriene antagonist, namely, montelukast, may protect asthmatic patients from a major cardiovascular event and, therefore, represent an innovative adjunct therapy to target an inflammatory component in cardiovascular disease. We performed an observational retrospective 3-year study on eight hundred adult asthmatic patients 18 years or older in Albania, equally distributed into two cohorts, exposed or nonexposed to montelukast usage, matched by age and gender according to information reported in the data collection. Patients with a previous history of myocardial infarction or ischemic stroke were excluded. In summary, 37 (4.6%) of the asthmatic patients, 32 nonexposed, and five exposed to montelukast suffered a major cardiovascular event during the 3-year observation period. All the cardiovascular events, in either group, occurred among patients with an increased cardiovascular risk. Our analyses demonstrate that, independent from gender, exposure to montelukast remained a significant protective factor for incident ischemic events (78% or 76% risk reduction depending on type of analysis). The event-free Kaplan–Meier survival curves confirmed the lower cardiovascular event incidence in patients exposed to montelukast. Our data suggest that there is a potential preventative role of montelukast for incident cardiac ischemic events in the older asthmatic population, indicating a comorbidity benefit of montelukast usage in asthmatics by targeting cysteinyl leukotriene-driven cardiac disease inflammation.
format Online
Article
Text
id pubmed-7838535
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78385352021-01-28 Montelukast Use Decreases Cardiovascular Events in Asthmatics Hoxha, Malvina Tedesco, Calogero C. Quaglin, Silvana Malaj, Visar Pustina, Linda Capra, Valerie Evans, Jilly F. Sala, Angelo Rovati, G. Enrico Front Pharmacol Pharmacology Cysteinyl leukotrienes are proinflammatory mediators with a clinically established role in asthma and a human genetic and preclinical role in cardiovascular pathology. Given that cardiovascular disease has a critical inflammatory component, the aim of this work was to conduct an observational study to verify whether the use of a cysteinyl leukotriene antagonist, namely, montelukast, may protect asthmatic patients from a major cardiovascular event and, therefore, represent an innovative adjunct therapy to target an inflammatory component in cardiovascular disease. We performed an observational retrospective 3-year study on eight hundred adult asthmatic patients 18 years or older in Albania, equally distributed into two cohorts, exposed or nonexposed to montelukast usage, matched by age and gender according to information reported in the data collection. Patients with a previous history of myocardial infarction or ischemic stroke were excluded. In summary, 37 (4.6%) of the asthmatic patients, 32 nonexposed, and five exposed to montelukast suffered a major cardiovascular event during the 3-year observation period. All the cardiovascular events, in either group, occurred among patients with an increased cardiovascular risk. Our analyses demonstrate that, independent from gender, exposure to montelukast remained a significant protective factor for incident ischemic events (78% or 76% risk reduction depending on type of analysis). The event-free Kaplan–Meier survival curves confirmed the lower cardiovascular event incidence in patients exposed to montelukast. Our data suggest that there is a potential preventative role of montelukast for incident cardiac ischemic events in the older asthmatic population, indicating a comorbidity benefit of montelukast usage in asthmatics by targeting cysteinyl leukotriene-driven cardiac disease inflammation. Frontiers Media S.A. 2021-01-13 /pmc/articles/PMC7838535/ /pubmed/33519477 http://dx.doi.org/10.3389/fphar.2020.611561 Text en Copyright © 2021 Hoxha, Tedesco, Quaglini, Malaj, Pustina, Capra, Evans, Sala and Rovati http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (http://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Hoxha, Malvina
Tedesco, Calogero C.
Quaglin, Silvana
Malaj, Visar
Pustina, Linda
Capra, Valerie
Evans, Jilly F.
Sala, Angelo
Rovati, G. Enrico
Montelukast Use Decreases Cardiovascular Events in Asthmatics
title Montelukast Use Decreases Cardiovascular Events in Asthmatics
title_full Montelukast Use Decreases Cardiovascular Events in Asthmatics
title_fullStr Montelukast Use Decreases Cardiovascular Events in Asthmatics
title_full_unstemmed Montelukast Use Decreases Cardiovascular Events in Asthmatics
title_short Montelukast Use Decreases Cardiovascular Events in Asthmatics
title_sort montelukast use decreases cardiovascular events in asthmatics
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838535/
https://www.ncbi.nlm.nih.gov/pubmed/33519477
http://dx.doi.org/10.3389/fphar.2020.611561
work_keys_str_mv AT hoxhamalvina montelukastusedecreasescardiovasculareventsinasthmatics
AT tedescocalogeroc montelukastusedecreasescardiovasculareventsinasthmatics
AT quaglinsilvana montelukastusedecreasescardiovasculareventsinasthmatics
AT malajvisar montelukastusedecreasescardiovasculareventsinasthmatics
AT pustinalinda montelukastusedecreasescardiovasculareventsinasthmatics
AT capravalerie montelukastusedecreasescardiovasculareventsinasthmatics
AT evansjillyf montelukastusedecreasescardiovasculareventsinasthmatics
AT salaangelo montelukastusedecreasescardiovasculareventsinasthmatics
AT rovatigenrico montelukastusedecreasescardiovasculareventsinasthmatics